Skip to content
Screener
Pacific Biosciences of California logo

Pacific Biosciences of California

PACB

Pacific Biosciences of California, Inc. is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions.

Market cap
$416.51M+12.7%
Revenue$159.3M+2.0%
Net income-$131.4M+75.1%
Free cash flow-$123.4M+19.0%
EPS (diluted)-$0.43+80.8%
Trailing twelve months · change vs. prior year

Earnings

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$43.8M
EPS estimate-$0.13

Financials

Q2 2026

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation & ratios

Valuation

See full
Market cap$416.51M+12.7%
Enterprise value$415.7M+13.7%
P/S2.6×+0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Current ratio4.9×-2.0×

Segments

By geography

See full
Americas$17.6M-0.4%
Europe, Middle East and Africa$14.4M+52.4%
Asia-Pacific$7.0M-44.8%

By product

See full
Consumable revenue$20.1M+6.2%
Instrument revenue$12.8M-9.3%
Service and other revenue$6.1M-9.4%

By segment

See full
Reportable Segment$39.0M-1.9%

Competitors

Profile

Pacific Biosciences of California, Inc. is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions. The company's core value proposition centers on its HiFi long-read sequencing technology, which provides scientists and clinical researchers with a complete and accurate view of genomes, transcriptomes, and epigenomes. Their systems are utilized to resolve genetically complex problems across human germline sequencing, oncology, and agricultural sciences.

Competitive position

A leading provider of long-read sequencing technology, positioned as a high-accuracy alternative to traditional short-read sequencing for complex genetic analysis.

GeographiesUnited States, Asia-Pacific, Europe, Mexico, Brazil, South Africa
Customer segmentsAcademic Research, Clinical Diagnostics, Pharmaceutical R&D, Agricultural Biotechnology
Business modelRazor-and-blade, Manufacturing, Service and Maintenance
SuppliersSemiconductor manufacturers, Specialized chemical suppliers, Third-party logistics carriers, Integrated circuit providers
CustomersAcademic and governmental research institutions, Commercial testing and service laboratories, Pharmaceutical and biotechnology companies, Agricultural research organizations
Listed2010
Employees796.0
CEOMark Van Oene
Websitepacb.com
FilingsSEC EDGAR

FAQ

What is Pacific Biosciences of California's market cap?
Pacific Biosciences of California (PACB) has a market capitalization of $416.5M and trades on NASDAQ.
What is Pacific Biosciences of California's revenue and profitability?
Pacific Biosciences of California generated $159.3M in trailing twelve-month revenue with a net loss of $131.4M, representing a net margin of -82.5%. Gross margin stands at 36.4%, with free cash flow of -$123.4M. The latest reported period is Q2 2026.
Who are Pacific Biosciences of California's competitors?
Pacific Biosciences of California's key competitors include Illumina, Inc., Revvity, Inc., Quanterix Corporation Common Stock, and others. These companies compete in similar markets and product categories.
Who does Pacific Biosciences of California partner with?
Pacific Biosciences of California's notable partners include SB Northstar LP, HiFi Solves Global Consortium.
What subsidiaries does Pacific Biosciences of California have?
Pacific Biosciences of California's subsidiaries include Apton Biosystems.
Where is Pacific Biosciences of California headquartered?
Pacific Biosciences of California is headquartered in United States of America and employs approximately 796 people. It has been publicly traded since 2010.